Royalty Report: Drugs, Cancer, Drug Discovery – Collection: 362432

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 9

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 9

Primary Industries

  • Drugs
  • Cancer
  • Drug Discovery
  • Stem cells
  • cell therapy
  • Biotechnology
  • Surgical
  • Autoimmune
  • Supply
  • Therapeutic
  • Test/Monitoring

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 362432

License Grant
Licensor grants an exclusive license, including the right to grant sublicenses, under the Licensed Patent Rights and Licensed Technology and Licensors interest in any Improvements, subject at all times to the restrictions and obligations under a Stanford Agreement with respect to the Stanford IP, to research, develop, test, obtain Regulatory Approval for, make, have made, use, have used, sell, offer for sale, have sold, import, have imported, export and have exported Licensed Products, including, without limitation, any Dimerizer included or utilized therein, in the Territory, for any and all uses within the Licensed Field during the Term, and to make, have made, use, import and export, in each case solely for research purposes, including pre-clinical IND-enabling toxicology and other pre-clinical studies, but not to conduct clinical trials with respect to or to obtain Regulatory Approval for, sell or commercialize, Licensed Products, including, without limitation, any Dimerizer included or utilized therein, for any indication other than the Primary Indications until the end of the Expansion Period and, if Licensee elects to add Additional Indications to the Licensed Field during the Expansion Period, for any indication other than the Primary Indications and the Additional Indications until the end of the Non-Cancer Expansion Period.

This agreement includes a non-exclusive grant back from Licensee to Licensor.

License Property
Licensor is the owner of or otherwise controls certain proprietary Licensed Patent Rights and Licensed Technology.

Licensors Dimerizer shall mean the compound known as xx1903, all analogs and derivatives of xx1903 and any Dimerizcr or salt thereof, where the composition of matter thereof or its use as a divalent ligand is, at any time during the Primary License Term, within the scope of a claim in any patent or patent application within the Licensed Patent Rights.

xx1903 is for the treatment of GvHD as an orphan drug.

GvHD shall mean a clinical condition involving acute or chronic adverse effects or symptoms resulting from the allogenic transplantation of bone marrow, hematopoietic or stem cells into a human being in which engrafted donor cells attack the patients organs and tissues which can be treated by activating cell signaling leading to apoptosis of the transplanted cells.

Cell Transplantation Indication shall mean GvHD or any other acute or chronic adverse clinical effect in a human being resulting from transplantation of bone marrow, hematopoietic or stem cells that can be treated by inducing apoptosis of transplanted cells, or in the case of a bone marrow, hematopoietic or stem cell product for transplantation that includes cells containing a gene coding for an Inducible Caspase, any disease or condition in a human being that can be treated by such product.

Licensed Products include  BPX-101 (formerly BP-GMAX-CDJ) , and, CaspaCIDe Donor Lymphocyte Infusion.

Field of Use
Licensed Field shall mean the treatment or prevention of the progression or occurrence in humans of any Primary Indication and/ or any Additional Indication, such as kidney cancer, or any noncancer indication, as the case may be.

Licensee is developing cell therapies to treat cancers and other chronic and life-threatening diseases.

IPSCIO Record ID: 336338

License Grant
Licensor, a non-profit health care organization, grants to Licensee the worldwide and exclusive license with a right to sublicense, under the Patent Rights, to make, have made, use, have used, offer for sale, have offered for sale, import, have imported, have sold and sell the Licensed Products, and to practice the Licensed Processes, in the Territory for the Field of Use to the end of the Term, unless sooner terminated as provided in this Agreement.
License Property
Rights relate to therapeutic compositions of modulated HSCs and methods for promoting reconstitution of the hematopoietic system using modulators of the prostaglandin pathway.

Licensor is the co-owner with a Hospital Corporation of certain Patent Rights.  The patents are Method to Modulate Hematopoietic Stem Cell Growth, and, Method to Enhance Tissue Regeneration.

ZON IND shall mean the investigational new drug application titled A Phase I Study of Reduced Intensity, Sequential Double Umbilical Cord Blood Transplantation Using Ex-Vivo 16,16 Dimethyl-Prostaglandin E2 Expanded Umbilical Cord Blood Units.

Field of Use
Licensee's HSC modulation platform focuses on the ex vivo pharmacologic optimization of hematopoietic stem cells, or HSCs, which are adult stem cells that regenerate all types of blood cells throughout a person’s lifespan. HSCs have been used for decades in a potentially curative procedure called hematopoietic stem cell transplant, or HSCT. This procedure is most commonly used in patients with hematologic malignancies to replace a diseased hematopoietic system with a healthy one. While over one million HSCT procedures have been performed to date, we believe HSCs have not been pharmacologically optimized to improve patient outcomes. Licensee'sHSC modulation platform has the potential to generate products that will improve patient outcomes in orphan indications by enhancing hematopoietic reconstitution through accelerated, durable engraftment, permitting greater donor matching flexibility, reducing the risk of major side effects and enabling the use of less toxic conditioning regimens.

Licensee's lead product candidate, ProHema, is a pharmacologically modulated HSC therapeutic derived from umbilical cord blood. Licensee has established human proof-of-concept for ProHema in the clinical setting by demonstrating enhanced and durable engraftment of HSCs within the bone marrow. Engraftment, which is the localization and integration of HSCs within a targeted tissue where they can produce new cells, is an important determinant of patient outcomes in HSCT. Licensee is presently advancing ProHema in Phase 2 clinical development for hematologic malignancies. Licensee is also pursuing the development of pharmacologically optimized HSC therapeutics for the treatment of certain lysosomal storage disorders, or LSDs, where HSCs have demonstrated the ability to home, or migrate, to and engraft within the central nervous system, or CNS.

IPSCIO Record ID: 383612

License Grant
Licensor grants an exclusive, even as to Licensor, except as required for Licensor to meet its development and supply obligations hereunder, right and license, with the right to sublicense, during the Term of this Agreement under the Licensor Intellectual Property and Licensors interest in any Joint Patent Rights and Joint Technology solely to research, develop, make, have made, use, sell, offer for sale and import Products in the Field in the Licensee Territory, and a non-exclusive right and license, with the right to sublicense, during the Term of this Agreement under the Licensor Intellectual Property to research, make, have made, use and export Products in the Field in North America.
License Property
Licensor is a stem cell therapeutic leader focused on developing and marketing products to treat medical conditions and possesses broad scientific and clinical leadership in the field of human mesenchymal stem cells (MSCs) and know-how, expertise and intellectual property rights pertaining to MSCs, including its Prochymal product and Chondrogen product.

Chondrogen shall mean any formulation, dosage form or delivery system that contains culturally expanded, undifferentiated, unmodified human MSCs for local delivery for the Articulating Orthopedic Indication and any Improvements thereto.

Prochymal shall mean any formulation, dosage form or delivery system suitable for Vascular Administration that contains culturally expanded, undifferentiated, unmodified human MSCs, and any Improvements thereto.

Ulcerative Colitis Indication shall mean the use of Prochymal for the treatment or prevention of ulcerative colitis.

Mesenchymal Stem Cells or MSCs shall mean the human formative pluripotential blast cells found inter alia in bone marrow, blood, dermis and periosteum that are capable of differentiating into any of the specific types of mesenchymal or connective tissues.

COPD Indication shall mean the use of Prochymal to treat chronic obstructive pulmonary disease.

Articulating Orthopedic Indication shall mean the use of Chondrogen for preventing or treating diseases, defects or conditions of articulating joints, including cartilage and meniscus repair, osteoarthritis, osteochondral defect repair, and the treatment of acute and chronic orthopedic pain within an articulating joint.

Crohns Indication shall mean the use of Prochymal to treat Crohns disease.

Diabetes Indication shall mean the use of Prochymal for the prevention or treatment of Type I diabetes.

GvHD Indication shall mean the use of Prochymal to treat or prevent graft versus host disease.

Cardiac Indication shall mean the use of Prochymal to treat or prevent acute myocardial infarction.

Pain Therapeutic shall mean use of Chondrogen for the mitigation or relief of orthopedic pain with a Statistically Significant duration of relief of at least one year.

Field of Use
Field shall mean with respect to Prochymal, all applications for the prevention or treatment of diseases, defects, or conditions in humans, and with respect to Chondrogen, the Articulating Orthopedic Indication.

IPSCIO Record ID: 7534

License Grant
Israeli Licensor hereby grants to Israeli Licensee an exclusive, royalty-bearing, worldwide license under Licensor’s rights in the Licensed Technology to research, have researched, develop, have developed, manufacture, have manufactured, use, market, distribute, offer for sale, sell, have sold, export and import Licensed Products and/or provide services relating thereto.
License Property
“Drug” means 4F-benzoyl- TN14003.

BL-8040 (formerly BKT-140) is for the treatment of acute myeloid leukemia, as well as other types of hematological cancer (the “Drug”).

BL-8040, is a novel short peptide that functions as a high-affinity antagonist for CXCR4, which we intend to develop for AML, and other hematological indications. BL-8040 mobilizes cancer cells from the bone marrow and may therefore sensitize these cells to chemo- and bio-based anti-cancer therapy. In addition, BL-8040 has demonstrated a direct anti-cancer effect by inducing apoptosis (cell death). Multiple pre-clinical studies have shown the safety and efficacy of BL-8040. BL-8040 also mobilizes stem cells from the bone marrow to the peripheral blood, enabling their collection for subsequent autologous or allogeneic transplantation in cancer patients.

Field of Use
BL-8040 is a novel peptide for the treatment of acute myeloid leukemia and other hematological indications.

IPSCIO Record ID: 279346

License Grant
Licensor grants to the Swiss Licensee a sole and exclusive, even as to Licensor, worldwide right and license under the Licensor Patents and Licensor Know-How to make, have made, use, offer for sale, sell and import Licensed Products in the Field.

Licensor grants a nonexclusive, nontransferable. limited right to use the Licensor trademark.

License Property
Licensor owns or controls patents and know-how related to a series of proprietary compounds which act as purine nucleoside phosphorylase inhibitors (PNP Inhibitors), including the compound known as –X-4208.

Compound means the PNP Inhibitor known as –X-4208.

Field of Use
The Field means the prevention or treatment of Autoimmune Indications and Transplantation Indications.

Autoimmune Indications means all indications that involve pathogenic consequences, including tissue injury, produced by autoantibodies or autoreactive T lymphocytes interacting with self epitopes, i.e., autoantigens.

Transplantation Indications means all indications that involve the suppression of rejection of transplanted organs, bone marrow or other tissue, including, without limitation, solid organ transplantation (including tolerance induction and xenotransplantation), bone marrow transplantation, graft versus host disease and cell transplantation.

BCX-4208 is for the prevention of acute rejection in transplantation and for the treatment of autoimmune diseases.

IPSCIO Record ID: 213098

License Grant
The Israeli Licensee signed an agreement with the Israeli Licensor to conduct a Phase I/II trial of PLX-PAD cell therapy for the treatment of Steroid-Refractory Chronic Graft-Versus-Host-Disease ('GvHD').
License Property
PLX-PAD – PLacental eXpanded cells are placenta-derived cells that are designed to be administered to patients without the need for tissue or genetic matching.
Field of Use
The Licensee is a developer of placenta-based cell therapy products.

Graft-versus-host disease (GvHD) is a medical complication following the receipt of transplanted tissue from a genetically different person. GvHD is commonly associated with stem cell transplant (bone marrow transplant), but the term also applies to other forms of tissue graft. Immune cells (white blood cells) in the donated tissue (the graft) recognize the recipient (the host) as foreign (nonself).

IPSCIO Record ID: 372535

License Grant
Licensor grants an exclusive, world-wide license under the Licensed Patents to import, make, have made, use, sell, offer for sale and have sold Licensed Products for the Field of Use.
License Property
Licensor has certain intellectual property rights related to nucleoside analog pharmaceuticals including Nicotinamide Adenine Dinucleotide and prodrugs of Cordycepin.

The patents relate to Nucleoslde Prodrugs Resistant to Metabolic Deactivatlon.

Field of Use
Cordycepin has been studied in a National Cancer Institute-sponsored Phase I clinical trial for treating TdT-positive ALL leukemia patients. The therapy depends upon the presence of TdT for its activity. TdT is a polymerase expressed in immature, pre-B, pre-T lymphoid cells, and acute lymphoblastic leukemia/lymphoma cells. TdT, and similar enzymes found in fungi and parasites, recognize Cordycepin and its analogues and add them onto growing nucleic acid chains thereby terminating synthesis of the nucleic acid and replication of the cell. Importantly, TdT expression in normal human tissue is limited to primitive lymphoid cells in the bone marrow and thymus, so most normal cells in the body are unaffected by the drug. In addition to effectively treating TdT-positive ALL and CML, Cordycepin can also be used to treat diffuse high-grade lymphoblastic lymphoma, which also expresses TdT.

IPSCIO Record ID: 7349

License Grant
The Licensee entered into a royalty Agreement with the Licensor and received the following assets from the Licensor
License Property
Certain patents and patent applications and all related active prosecution cases, trade secrets, know-how and certain other intellectual property rights, and all of the Licensor's goodwill with respect to the technology directly related to the research, development and commercialization of certain products and know-how related to hES cells;

Certain biological materials and reagents (including master and working cell banks, original and seed banks, and research, pilot and GMP grade lots and finished product);

Certain regulatory filings for clinical trials for GRNOPC-I for spinal cord injury, including the investigational new drug applications filed with the United States Food and Drug Administration for Licensor’s Phase I safety study of oligodendrocyte progenitor (GRNOPC-1) cells in patients with neurologically complete, subacute spinal cord injury (Protocol No. CP35A007), and long term follow up of subjects who received GRNOPC1 (Protocol No. CP35A008), and the clinical trial for VAC1 for acute myelogenous leukemia, including a Phase I/II study of active immunotherapy with GRNVAC1, autologous mature dendritic cells transfected with mRNA encoding human telomerase reverse transcriptase (hTERT), in patients with acute myelogenous leukemia (AML) in complete remission (Protocol No. CP06-151).

US Patent 6,800,480 – Methods and Materials for the Growth of Primate-Derived Primordial Stem Cells in Feeder-Free Culture
US Patent 7,413,902 – Feeder-Free Culture Method for Embryonic Stem Cells
US Patent 6,440,735 – Dendritic Cell Vaccine Containing Telomerase Reverse Transcriptase for the Treatment of Cancer
US Patent 7,402,307 – Method for Identifying and Killing Cancer Cells
US Patent 7,824,849 – Cellular Telomerase Vaccine and Its Use for Treating Cancer
US Patent 7,560,281 – Use of TGF Beta Superfamily Antagonists to Make Dopaminergic Neurons from Embryonic Stem Cells
US Patent 8,252,586 – Neural Cell Populations from Primate Pluripotent Stem Cells
US Patent 8,153,428 – Use of TGF Beta Superfamily Antagonists and Neurotrophins to Make Neurons from Embryonic Stem Cells
US Patent 6,667,176 – cDNA Libraries Reflecting Gene Expression During Growth and Differentiation of Human Pluripotent Stem Cells
US Patent 7,041,438 – Use of Human Embryonic Stem Cells for Drug Screening and Toxicity Testing
US Patent 7,413,904 – Embryonic Stem Cells Having Genetic Modifications
US Patent 7,410,798 – Culture System for Rapid Expansion of Human Embryonic Stem Cells
US Patent 7,297,539 – Medium for Growing Human Embryonic Stem Cells
US Patent 7,455,983 – Medium for Growing Human Embryonic Stem Cells
US Patent 8,097,458 – Culture System for Rapid Expansion of Human Embryonic Stem Cells
US Patent 6,642,048 – Conditioned Media for Propagating Human Pluripotent Stem Cells
US Patent 6,458,589 – Hepatocyte Lineage Cells Derived from Pluripotent Stem Cells
US Patent 6,506,574 – Hepatocyte Lineage Cells Derived from Pluripotent Stem Cells
US Patent 7,256,042 – Process for Making Hepatocytes from Pluripotent Stem Cells
US Patent 7,282,366 – Hepatocytes for Therapy and Drug Screening Made From Embryonic Stem Cells
US Patent 7,473,555 – Protocols for Making Hepatocytes from Embryonic Stem Cells
US Patent 8,148,151 – Differentiation of Primate Pluripotent Cells to Hepatocyte-Lineage Cells
US Patent 6,833,269 – Making Neural Cells for Human Therapy or Drug Screening from Human Embryonic Stem Cells
US Patent 8,148,148 – Neural Progenitor Cell Populations
US Patent 8,252,585 – Neural Progenitor Cell Populations
US Patent 7,250,294 – Screening Small Molecule Drugs Using Neural Cells Differentiated from Human Embryonic Stem Cells
US Patent 7,763,463 – Use of Cyclic AMP and Ascorbic Acid to Produce Dopaminergic Neurons from Embryonic Stem Cells
US Patent 6,576,464 – Differentiated Cells Suitable For Human Therapy
US Patent 6,921,665 – Selective Antibody Targeting of Undifferentiated Stem Cells
US Patent 7,732,199 – Process for Making Transplantable Cardiomyocytes from Human Embryonic Stem Cells
US Patent 7,763,464 – Differentiation Protocol for Making Human Cardiomyocytes
US Patent 7,452,718 – Direct Differentiation Method for Making Cardiomyocytes from Human Embryonic Stem Cells
US Patent 7,897,389 – Direct Differentiation Method for Making Cardiomyocytes from Human Embryonic Stem Cells
US Patent 7,851,167 – Differentiation Protocol for Making Human Cardiomyocytes

US Patent Application 13/561,296 – Neural Cell Populations from Primate Pluripotent Stem Cells
US Patent Application 12/170,219 – Culture System for Rapid Expansion of Human Embryonic Stem Cells
US Patent Application 12/710,078 – Culture System for Rapid Expansion of Human Embryonic Stem Cells
US Patent Application 13/323,567 – Culture System for Rapid Expansion of Human Embryonic Stem Cells
US Patent Application 11/917,993 – Suspension Culture of Human Embryonic Stem Cells
US Patent Application 12/277,136 – Protocols for Making Hepatocytes from Embryonic Stem Cells
US Patent Application 13/558,078 – Neural Progenitor Cell Populations
US Patent Application 11/359,341 – Differentiated Cells Suitable For Human Therapy
US Patent Application 11/471,916 – Differentiation of Primate Pluripotent Stem Cells to Cardiomyocyte-Lineage Cells

Field of Use
The Licensee is a biotechnology company focused on the emerging field of regenerative medicine, with core technologies centered on stem cells capable of becoming all of the cell types in the human body, a property called pluripotency.

IPSCIO Record ID: 289229

License Grant
For Licensed Biologic Products, Licensor grants an exclusive, sub-licensable, worldwide license to Licensee to research, develop, use, make, have made, sell, offer for sale, import or export any Licensed Biologic Products in the Therapeutic Field.

For Licensed Drug Products, Licensor grants an exclusive, sub-licensable, worldwide license to research, develop, use, make, have made, sell, offer for sale, import or export any Licensed Drug Products in the Therapeutic Field.  Notwithstanding the foregoing, Licensee may sublicense a Licensed Drug Product, provided that Licensee has at least one pending patent claim covering such product.

For Developed Drug Products, Licensor grants a non-exclusive, sub-licensable, worldwide license to research, develop, use, make, have made, sell, offer for sale, import or export any Developed Drug Products in the Therapeutic Field. Notwithstanding the foregoing, Licensee may sublicense a Developed Drug Product, provided that Licensee has at least one pending patent claim covering such product.

For Licensed Diagnostic Products, Licensor grants a non-exclusive, sub-licensable, worldwide license to research, develop, use, make, have made, sell, offer for sale, import or export any Licensed Diagnostic Product in the Diagnostic Field. Licensees right to sublicense a Licensed Diagnostic Product will be limited to applications reasonably determined to be necessary for successful commercialization of the Licensed Biologic Product or Licensed Drug Product and subject to Licensors approval, which will not be unreasonably withheld.

License Property
Licensor has intellectual property related to the receptor to the Tumor necrosis factor-like weak inducer of apoptosis, or Tweak-R.

Tweak-R shall mean the receptor to the tumor necrosis factor like weak inducer of apoptosis, which is the molecule designated CG 17M42 by HGS.

Field of Use
'Indication' is a therapeutic indication for a particular disease, and, for example, cancer indications within different organs (e.g., lung cancer and colon cancer) shall not represent different indications.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.